Towards quantifying the reciprocal associations between frequency of cannabis use and alcohol consumption: a cross-lagged analysis from the CONSTANCES cohort

Guillaume Airagnes, Joane Matta, Frédéric Limosin, Nicolas Hoertel, Marcel Goldberg, Marie Zins, Cedric Lemogne

ABSTRACT

Objective Disentangle the temporal relationships between frequency of cannabis use and alcohol consumption.

Methods A cross-lagged model providing standardised coefficients (SCs)±their standard errors in 13 255 men and 13 696 women enrolled in 2015 or 2016 in the French population-based ‘CONSulTANts des Centres d’Examens de Santé’ (CONSTANCES) cohort. Cannabis use was categorised as follows: ‘No use during the past 12 months’, ‘Use during the past 12 months but not in the past month’ and ‘Use in the past month’ for cannabis use at baseline, and No use during the past 12 months, ‘Use less than once per month’ and ‘Use once per month or more’ for cannabis use at 1 year of follow-up. Alcohol consumption was measured at baseline and at 1 year of follow-up and three categories were determined: low risk (<28 drinks per week in men; <14 drinks per week in women), moderate risk (≥28 and<42 in men; ≥14 and<28 in women) and high risk (≥42 in men; ≥28 in women). Analyses were adjusted for age, sex, education, income, tobacco consumption, self-rated health status and depressive symptoms.

Results Both associations from alcohol to cannabis and from cannabis to alcohol were significant (SC=0.02±0.01 with p=0.003 and SC=0.06±0.01 with p<0.001, respectively). However, the SC of the association from cannabis to alcohol was three times higher than the opposite association (p<0.001). After stratification for sex, SCs of the association from cannabis to alcohol were more than two times higher than for the opposite association in men, and more than four times higher in women (both p<0.001).

Conclusions The association between frequency of cannabis use and subsequent alcohol consumption was stronger than the opposite association. This finding encourages considering the risk of increased alcohol consumption among cannabis users.

INTRODUCTION

Substance use is one of the first leading preventable cause of premature death worldwide. At a population level, alcohol, tobacco and other drugs, especially cannabis, which is the most commonly illicit drug used, are among the leading risk factors for morbidity and mortality worldwide. In addition, co-use of these substances may be associated with increased levels of consumption, dependency and deleterious health consequences. Temporal relationships have been particularly described in the co-use of tobacco and cannabis in one hand, and in the co-use of tobacco and alcohol in the other hand. Although associations between cannabis and alcohol use have been also described, the literature poorly examined whether the consumption of one could increase the consumption of the other over time, besides acute intoxication.

The ongoing policy changes in several countries regarding legalisation or decriminalisation of cannabis use should encourage
examining the potential detrimental role of cannabis on alcohol consumption, even in occasional cannabis users. As a matter of fact, higher levels of alcohol consumption were reported among cannabis users, as well as greater negative social and behavioural consequences of their alcohol use. Regarding the direction of the association, a longitudinal study found a higher incidence of alcohol abuse or dependence over a 3-year follow-up period among subjects with cannabis use compared with those who did not use cannabis at baseline. This might be interpreted as a harmful consequence of cannabis use on the risk of alcohol use disorder. However, this association might reflect the increased risk of developing another addictive behaviour after the occurrence of a first one, irrespective of the type of the substance that was initially used. In other words, the risk of developing an addictive behaviour when the first one is present is high, but the extent to which the reciprocal association is similar, stronger or smaller remains unknown. However, this knowledge would be helpful for both clinicians and public health policy-makers to improve information and targeted screening.

We took advantage of the longitudinal data from the French population-based CONSTANCES cohort to disentangle the temporal relationships between frequency of cannabis use and alcohol consumption using a cross-lagged model. The cross-lagged model can provide information on the direction of the association between cannabis and alcohol by quantifying the magnitude of the two directions simultaneously while taking into consideration potential confounding factors. We hypothesised a significantly higher magnitude of the association from cannabis to alcohol compared with the opposite association, suggesting that this direction would prevail over the other.

METHODS
Cohort description
The French population-based CONSTANCES cohort enrolled volunteers aged 18–69 years at baseline according to a random sampling scheme stratified on age, gender, socioeconomic status and region of France. Among the different procedures conducted with participants, they completed annual self-administered questionnaires on their lifestyle, health, social and personal characteristics.

Patient and public involvement
Patients or members of the public were not involved in the design of this study, nor in its implementation. Patients and general public will be informed of the results of the study via publication.

Participants
In the present study, we used data from 47 673 participants enrolled in the CONSTANCES cohort in 2015 or 2016 and to whom the questionnaire on alcohol habits had been sent at both baseline and 1 year of follow-up. Among them, 37 588 (78.8%) had no missing data regarding their alcohol, cannabis and tobacco use at baseline. Complete data for substance use were available at follow-up for 27 696 participants (73.7%). Cannabis use was illicit in France when the data were collected. Among the non-responders at follow-up, 9276 (87.3%) did not respond to the entire questionnaire whereas 1361 (12.7%) did not respond to the questions related to substance use. Finally, since we were interested in examining the changes in alcohol consumption among persons likely to consume alcohol, the 745 participants who reported to having never consumed alcohol in their life were excluded. Thus, a total of 26 951 participants were included in the present study. A description of their characteristics before and after attrition is presented in online supplemental table 1.

Measurements
Cannabis use at baseline and at follow-up
The questionnaire at baseline included three binary questions that were used to determine cannabis consumption: (1) ‘Have you ever used cannabis (hashish, marijuana, weed, joint, pot)?’, (2) ‘Have you used cannabis in the past 12 months?’ and (3) ‘Have you used cannabis in the past thirty days?’. From this information, a categorical variable was computed as follows: ‘No use during the past 12 months’, ‘Use during the past 12 months but not in the past month’ and ‘Use in the past month’.

The questionnaire at 1 year of follow-up included the following binary question: ‘Over the past 12 months, have you used cannabis (hashish, marijuana, weed, joint, pot)?’. Those who answered ‘yes’ were asked to further provide information on how often they had used cannabis with the following options: ‘Less than once per month’, ‘Once to twice per month’, ‘At least once per week’, ‘Every day, or nearly’. From this information, a categorical variable was computed as follows: No use during the past 12 months, ‘Use less than once per month’ and ‘Use once per month or more’. Since measurements of cannabis frequency of use slightly differ at baseline and at follow-up, sensitivity analyses were conducted. In these analyses, we used the answers to the following question: ‘How many times have you used cannabis in the past 12 months?’, that was asked among those who reported a cannabis use in the past 12 months prior to baseline. To compensate for a potential under-estimation of the number of monthly users at baseline, we also considered as users of once per month or more those who did not report a cannabis use in the past 30 days but who reported ≥12 times of cannabis use in the past 12 months. Conversely, to attenuate a potential over-estimation of the number of monthly users at baseline, we considered as users of less than once per month those who reported cannabis use in the past 30 days but who reported <12 times of cannabis use in the past 12 months.
Alcohol use at baseline and at follow-up

At both baseline and 1 year of follow-up, participants reported their daily alcohol consumption during the past week in number of drinks, considering that a drink includes 10 g of alcohol according to the standard in France. Precisely, participants reported their mean number of drinks per day from ‘Monday to Thursday’, and their number of drinks on ‘Friday’, ‘Saturday’ and ‘Sunday’. These numbers were added after having multiplied by 4 the sum corresponding to the line from Monday to Thursday in order to compute the number of drinks per week. Thus, three risk categories according to the level of alcohol consumption were built based on the WHO guidelines: alcohol consumption at low (<28 drinks per week in men; <14 drinks per week in women), moderate (≥28 and <42 in men; ≥14 and <28 in women) or high risk (≥42 in men; ≥28 in women).22

Covariables at baseline

The following sociodemographic variables were obtained from the baseline questionnaire: age, sex, education coded in five levels based on the 2011 International Standard Classification of Education, household income (ie, <€2100; €2100–2800; €2800–4200; >€4200/month) and marital status (ie, single or living with a partner). Education and household income were considered as ordinal representation of underlying sets of continuous units (ie, years of education and amount of money in euros per month); thus, these two variables were introduced as continuous variables in the statistical analyses. Daily tobacco consumption was computed as a continuous variable in cigarettes per day from the cumulative number of tobacco consumption per day whatever the product used (eg, common cigarette, cigar and pipe). Self-rated health status was assessed as a continuous variable by answering the following question: ‘How do you judge the state of your general health compared to a person of your surrounding of the same age’ on an 8-point like scale (1=very good, 8=very poor). Depressive symptoms were assessed as a continuous variable using the total score at the Center of Epidemiologic Studies Depression scale, ranging from 0 to 60.

Statistical analyses

The association between the two main outcomes and predictors of interest (ie, cannabis and alcohol at both baseline and follow-up) was tested using a cross-lagged model. The cross-lagged model is a structural equation model that considers all variables together, along with the covariables. In a cross-lagged model, results are presented as standardised coefficients which correspond to the coefficients of the regressions that are standardised to allow comparing the relative effects of two variables on each other. Conditional on their standard errors, the comparison of these standardised coefficients can determine which variable has a stronger effect on the other, thus informing on which direction of the association predominates over the other. Cross-lagged analyses were conducted with SAS Proc Calis (SAS, V.9.4). As described in this SAS procedure, standardised coefficients are obtained by introducing standardised variables in the models, that is, variables that have been centred and divided by their SD whether they consist of ordered categories or whether they are binary or continuous.

Frequency of cannabis use and alcohol consumption at both baseline and 1 year of follow-up were included in the model as ordinal variables, that is, ordinal representations of underlying sets of continuous units. Furthermore, prior findings suggested dose-dependent associations of these variables with detrimental outcomes. Residuals were allowed to correlate. Standardised coefficients were obtained in order to compare both direct effects (ie, from alcohol to cannabis and from cannabis to alcohol). The model was adjusted for the following covariables at baseline: age, sex, education, household income, marital status, depressive symptoms and self-rated health status. Covariables were allowed to correlate. In the path model, because we sought to examine simultaneously all path coefficients, no paths in any of the models were fixed to zero. Therefore, goodness-of-fit measures are not relevant in evaluating these models since they do not inform on the ‘correctness’ of the models but rather provide only a summary of how well the observed correlations match the model when several paths are fixed at zero. Some fit indices are however reported in the results order to show the goodness of fit of the model using the following cut-offs: Standardized Root Mean squared Residual (SRMR)<0.08, Goodness of Fit Index (GFI)>0.95, Root Mean Square Error of Approximation (RMSEA)<0.05 and Normed Fit Index (NFI)>0.95. Since substance use patterns could differ according to sex, the analysis of the cross-lagged model has been repeated by stratifying for sex.

To test the robustness of our results, we reproduced the analyses by introducing alcohol and cannabis use as binary variables (<14 drinks per week in women and <28 drinks per week in men versus ≥14 drinks per week in women and ≥28 drinks per week in men for alcohol use, and no consumption in past 12 months versus consumption in the past 12 months for cannabis use). Included subjects had complete data regarding dependent variables and tobacco consumption. We had missing data for the other variables, except for age and sex (mean percentage of missing data: 5.0%, going from 1.0% to 13.5%). Imputation by stochastic regressions was used to deal with these missing data. Statistical significance was evaluated with an alpha a priori set at 0.05.

RESULTS

A total of 13 255 (49.2%) men and 13 696 (50.8%) women were included, with a mean age of 47.5 (SD=13.4). Their characteristics at baseline are presented in table 1. At follow-up, 973 (3.6%) and 629 (2.3%) of the participants used cannabis less than once a month and once a month or more, respectively. At follow-up, 2272 (8.4%) and
818 (3.0%) of the participants consumed alcohol with moderate and high risks, respectively.

The results of the cross-lagged analysis are presented in figure 1. This model showed a good fit: SRMR=0.020, GFI=1.000, RMSEA=0.033 (90% CI 0.030 to 0.035) and NFI=0.987. Both associations from alcohol to cannabis and from cannabis to alcohol were significant: standardised coefficient=0.02±0.01 with p=0.003 and standardised coefficient=0.06±0.01 with p<0.001, respectively. However, the standardised coefficient of the association from cannabis to alcohol was three times higher than the opposite association (Z=−4.65; p<0.001). The standardised coefficients for all the covariables are presented in online supplemental table 2.

The results of the cross-lagged analysis after stratification for sex are presented in figure 2. These models showed good fits: SRMR=0.020, GFI=1.000, RMSEA=0.033 (90% CI 0.030 to 0.035) and NFI=0.987; SRMR=0.020, GFI=1.000, RMSEA=0.033 (90% CI 0.030 to 0.035) and NFI=0.987, in men and women, respectively. In men, the direct effect from alcohol to cannabis was significant (standardised coefficient=0.02±0.01 with p=0.047). The

### Table 1 Characteristics of included participants at baseline

| Categorical variables                                      | All participants | Men | Women |
|-------------------------------------------------------------|------------------|-----|-------|
| N=26951                                                     | N=13255          | N=13696 |
| **N**                                                       | **%**            | **N** | **%** |
| Education level*                                           |                  |      |       |
| Early childhood education and primary education              | 358              | 1.3  | 200   | 1.5  |
| Lower secondary education                                    | 1151             | 4.3  | 600   | 4.5  |
| Upper secondary education and postsecondary non-tertiary education | 8267             | 30.7 | 4561  | 34.4 |
| Short-cycle tertiary education and Bachelor's or equivalent level | 9873             | 36.6 | 4059  | 30.6 |
| Master's or equivalent level and Doctoral or equivalent level | 7302             | 27.1 | 3835  | 28.9 |
| **Household income (in euros per month)**                   |                  |      |       |
| Less than 2100                                              | 4423             | 16.4 | 1871  | 14.1 |
| From 2100 to 2800                                           | 4084             | 15.2 | 1859  | 14.0 |
| From 2800 to 4200                                           | 9140             | 33.9 | 4605  | 34.7 |
| More than 4200                                              | 9304             | 34.5 | 4920  | 37.1 |
| **Marital status**                                          |                  |      |       |
| Living with a partner                                       | 19744            | 73.3 | 10138 | 76.5 |
| Single                                                      | 7207             | 26.7 | 3117  | 23.5 |
| **Alcohol use risk categories†**                            |                  |      |       |
| Low                                                         | 24631            | 91.4 | 12295 | 92.8 |
| Moderate                                                    | 1797             | 6.7  | 643   | 4.9  |
| High                                                        | 523              | 1.9  | 317   | 2.4  |
| **Cannabis frequency of use**                               |                  |      |       |
| Not in the past 12 months                                   | 24875            | 92.3 | 12007 | 90.6 |
| In the past 12 months but not in the past month             | 1088             | 4.0  | 619   | 4.7  |
| In the past month                                           | 988              | 3.7  | 629   | 4.7  |
| **Continuous variables**                                   | **Mean**         | **SD** | **Mean** | **SD** | **Mean** | **SD** |
| Age                                                        | 47.5             | 13.4 | 48.5  | 13.3 | 46.6  | 13.4 |
| Number of cigarettes per day                                | 1.4              | 4.4  | 1.6   | 4.9  | 1.3   | 3.9  |
| CESD total score                                            | 14.1             | 5.3  | 13.1  | 4.9  | 15.0  | 5.4  |
| Self-rated health status‡                                     | 2.7              | 1.3  | 2.7   | 1.3  | 2.7   | 1.3  |

*According to the 2011 International Standard Classification of Education (ISCED) classification.
†According to the 2000 WHO guidelines as follows: low risk (≤28 drinks per week in men; ≤14 drinks per week in women), moderate risk (>28 and ≤42 in men; >14 and ≤28 in women) and high risk (>42 in men; >28 in women).
‡From 1=’Very good general health’ to 8=’Very poor general health’.
CESD, Center of Epidemiologic Studies Depression Scale.
direct effect from cannabis to alcohol was also significant (standardised coefficient=0.05±0.01 with p<0.001). However, the standardised coefficient of the association from cannabis to alcohol was more than two times higher than the opposite association (Z=-2.44 with p=0.010).

In women, the direct effect from alcohol to cannabis was significant (standardised coefficient=0.02±0.01 with p=0.043). The direct effect from cannabis to alcohol was also significant (standardised coefficient=0.09±0.01 with p<0.001). However, the standardised coefficient from cannabis to alcohol was more than four times higher than the opposite association (Z=-5.81 p<0.0001).

In sensitivity analyses, introducing cannabis and alcohol as binary outcomes rather than categorical ones lead similar results, that is, significant associations from alcohol to cannabis and from cannabis to alcohol use, with a significantly higher effect size for the association from cannabis to alcohol than for the opposite association (online supplemental figure 1). Finally, overestimating or underestimating the frequency of cannabis use lead to similar results (data not shown).

DISCUSSION
Our aim was to disentangle the temporal relationships between frequency of cannabis use and alcohol consumption in a large prospective cohort. In a cross-lagged model, we found that the magnitude of the association from cannabis to alcohol was significantly higher than the opposite (three times higher in the main analysis). After stratification for sex, the higher magnitude of the associations from cannabis to alcohol than the opposite association persisted, with a stronger association in women. All these analyses were adjusted for sociodemographic factors, overall health status and depressive symptoms.

This study has some strengths. Its longitudinal design as well as the use of a cross-lagged model allows quantifying and comparing the coefficients of the direct effects of frequency of cannabis use on alcohol consumption with the opposite association. Both main predictors/outcomes of interest were measured at both baseline and 1-year follow-up in a national population-based cohort having a large sample. In addition, sociodemographic and clinical variables were included in our model to control for potential confounding effects.

This study has also some limitations. First, the CONSTANCES cohort is not representative of the French general population. Thus, our findings may not apply to the same extent to other settings. In particular, participants were aged from 18 to 69 years at inclusion, thus limiting our interpretations to this subgroup. Moreover, all the participants to the CONSTANCES cohort were affiliated to the French General Social Security Regime; thus, certain professional categories could not be represented since they are affiliated to other social regimes, such as independent workers, farmers and craftsmen. Furthermore, the voluntary nature of participation in an epidemiologic cohort leads to selection biases. As it is usually found, there is an under-representation of people with a poor health status in the CONSTANCES cohort (eg, low self-rated health, severe depressive symptoms and very high levels of substance use). Thus, our findings might not apply to people whose health is the most impaired. Second, there was a 28.3% attrition rate at follow-up. Although one may wonder whether between-substance difference in response rate at follow-up may
have biased our results toward one association (eg, differential response rate due to the illicit nature of cannabis in France), it is noteworthy that there was a similar rate of non-responders who did not fill specifically their alcohol and cannabis consumption at follow-up, that is, 358 (3.37%) and 365 (3.43%), respectively. Thus, such attrition might have increased a selection bias toward healthier participants but it is unlikely that such bias could act differently on the two substances. Third, the observational nature of the data restricts the possibility of drawing confirmed causality. Fourth, although the results were adjusted for several confounders, some other shared vulnerability factors to both cannabis and alcohol use, such as personality, were not taken into account. These unmeasured confounders may explain to some extent the bidirectional relationship but are unlikely to account for our main result, showing that one direction may substantially prevail on the other.

We found the well-known reciprocal associations between cannabis and alcohol use, which are consistent with the increased likelihood of using a second substance when an individual is already using one, partly because of shared individual and environmental vulnerability factors. Importantly, and in accordance with our a priori hypothesis, we also found that the association between frequency of cannabis use and subsequent alcohol consumption was stronger than the opposite association. This finding is in agreement with the role of the endocannabinoid system on both cannabis and alcohol reinforcement and with a potential buffering role of cannabis cues on subsequent alcohol cues. This finding is also in line with prior studies regarding the increased risk of alcohol use disorder according to cannabis use. Furthermore, the association between frequency of cannabis use and subsequent alcohol consumption was stronger in women. Women could be particularly prone to experience more negative consequences of cannabis use when they also use alcohol. Men have usually a higher level of alcohol consumption compared with women, which may reduce the range of variation in consumption in response to other behaviours. This potential novel finding should be further examined in future studies focusing on gender differences.

At an individual level, our findings encourage developing combined treatments for both substances, especially since a treatment focused on cannabis use has shown benefits on alcohol use as well among patients having co-occurring disorders for both alcohol and cannabis. At a population level, it is noteworthy that the present study deals with very frequently used substances. Indeed, cannabis use is widespread, and even low frequencies of use were associated with subsequent increased alcohol consumption in the present study. Therefore, public health campaigns promoting cannabis cessation should include the potential benefits of such cessation on alcohol consumption. Further studies should focus not only on the level of alcohol consumption but also on the role of the frequency of cannabis co-use on alcohol-related harms. In conclusion, the present study encourages having an increased vigilance regarding the risk of increased alcohol consumption among cannabis users.

Contributors GA: conceptualisation, methodology, software, writing - original draft. JM: methodology, software, writing - review and editing, validation. FL: writing - review and editing, project administration, supervision, validation. NH: writing - review and editing, visualisation, validation. MG: writing - review and editing, project administration, data curation, resources, investigation, validation. MZ: writing - review and editing, project administration, data curation, resources, investigation, supervision, validation. CL: methodology, writing - review and editing, visualisation, supervision, validation. GA confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Funding There are no funders to report for this specific submission. The CONSTANCES cohort is supported by the Caisse Nationale d’Assurance Maladie CNAM. CONSTANCES is accredited as a “National Infrastructure for Biology and health” by the governmental Investissements d’avenir program and was funded by the Agence nationale de la recherche (ANR-11-INBS-0002 Grant). CONSTANCES also receives funding from L’Oréal, MSD, AstraZeneca and Lundbeck managed by INSERM-Transfert. None of the authors are salaried by the funders of the CONSTANCES cohort. The funders did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests GA has received speakers and/or consulting fees from Pfizer, Lundbeck, Zentiva and Pierre Fabre, outside the submitted work. FL has received speaker and/or consulting fees from Janssen-Cilag, Cephalon, Servier, and Lundbeck, outside the submitted work. CL has received speakers and/or consulting fees from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by the CONSTANCES cohort. The funders did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Personal health data underlying the findings of our study are not publicly available due to legal reasons related to data privacy protection. However, the data are available upon request to all interested researchers after authorisation of the French “Commission nationale de l’informatic et des libertés”. The CONSTANCES email address is contact@constances.fr.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Guillaume Airagnes http://orcid.org/0000-0002-3494-5083
Joanne Matta http://orcid.org/0000-0002-9123-6726
REFERENCES

1 WHO. Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization, 2009.

2 Peacock A, Leung J, Larnay S, et al. Global statistics on alcohol, tobacco and illicit drug use. 2017 status report. Addiction 2018;113:1960–26.

3 Verplaatser TL, Mckee SA. An overview of alcohol and tobacco/nicotine interactions in the human laboratory. Am J Drug Alcohol Abuse 2017;43:186–96.

4 Hayaki J, Anderson BJ, Stein MD. Dual cannabis and alcohol use disorders among young adults: problems magnified. Subst Abus 2016;37:579–83.

5 Linden-Carmichael AN, Mallatta KE, Sell N, et al. Are Co-users of alcohol and marijuana more willing to experience consequences from drinking? A longitudinal examination among first-year college students. Alcohol Clin Exp Res 2015;39:1567–74.

6 Goodwin RD. Impact of cannabis use on nicotine and tobacco use outcomes. Nicotine Tob Res 2020;22:1257–9.

7 Agrawal A, Budney AJ, Lynskey MT. The co-occurring use of alcohol and cannabis: a review. Addiction 2012;107:1221–33.

8 Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict 2015;24:105–16.

9 McClure EA, Rabin RA, Lee DC, et al. Treatment implications associated with cannabis and tobacco Co-Use. Curr Addict Rep 2020;7:533–44.

10 Walsh H, McNeill A, Purssell E, et al. Smoking and cannabis use: an ecological momentary assessment of co-use in young adults. Addiction 2019;114:408–16.

11 Beard E, West R, Michie S, et al. Does substance use explain social differences in terms of depression? findings from the Constances cohort. Compr Psychiatry 2020;102:152203.

12 Airagnes G, et al. BMJ Open 2022;12:e052819. doi:10.1136/bmjopen-2021-052819